Supplementary Table 1. The numbers of patients taking different insulin therapy combined with different oral hypoglycemic drugs

<table>
<thead>
<tr>
<th></th>
<th>GLP-1RA</th>
<th>DPP-4i</th>
<th>Metformin</th>
<th>α-glucosidase inhibitors</th>
<th>Sulfonylur eas/glinides</th>
<th>TZDs</th>
<th>SGLT2i</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glargine</td>
<td>10</td>
<td>57</td>
<td>168</td>
<td>246</td>
<td>241</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>Detemir</td>
<td>7</td>
<td>29</td>
<td>63</td>
<td>44</td>
<td>56</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Biphasic aspart</td>
<td>3</td>
<td>16</td>
<td>109</td>
<td>125</td>
<td>17</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Biphasic lispro</td>
<td>3</td>
<td>13</td>
<td>48</td>
<td>61</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Biphasic human insulin</td>
<td>1</td>
<td>3</td>
<td>44</td>
<td>47</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Human insulin</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>10</td>
<td>9</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Insulin aspart</td>
<td>1</td>
<td>2</td>
<td>5</td>
<td>24</td>
<td>12</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Glargine+aspart</td>
<td>7</td>
<td>23</td>
<td>89</td>
<td>48</td>
<td>38</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Detemir+aspart</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>